Blood GlucoseNCT07572513
Slowly Digestible Carbohydrates for GLP-1 Secretion
A study testing Raw Corn Starch in people with Blood Glucose and GLP-1, run by Purdue University at 1 site in United States.
Trial summary
The goal of this clinical trail is to learn if the hormone, glucagon-like peptide-1 (GLP-1), is stimulated by slowly digestible carbohydrates (SDCs) in healthy adults. In the current study, researchers will observe the amount of SDC that results in clinically meaningful levels of GLP-1, shown by an increase in… Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Blood Glucose, GLP-1, Satiety
- What is being tested?
- Raw Corn Starch
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 17 participants
- Where
- 1 siteUnited States
- Study dates
- 2 Jun 2026to 27 Aug 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy population
- BMI between 18.5 and 24.9 kg/m2
- Adults 18 - 45 years old
- Men or women
- Able to read/speak English
- Fasting blood glucose levels ≤100 mg/dL
- HbA1c ≤ 5.7%
Who cannot join
- Participants with 18 > Years of Age > 45 will be excluded.
- Subjects with 18.5 kg/m² > BMI > 24.9 kg/m² will be excluded.
- Diabetic individuals will be excluded.
- Individuals with history of gastrointestinal disease will be excluded from the study.
- Pregnant or nursing women will also be excluded.
- Individuals taking GLP-1 medications, or on weight-loss diets or restrictive eating patterns.
- Individuals suffering from dairy or gluten intolerance or allergies will be excluded.
Trial locations and contacts
1 site in 1 country.
United States1 site
Clinical Research Center at Purdue University
West Lafayette, Indiana, 47907
About this study
The goal of this clinical trail is to learn if the hormone, glucagon-like peptide-1 (GLP-1), is stimulated by slowly digestible carbohydrates (SDCs) in healthy adults. In the current study, researchers will observe the amount of SDC that results in clinically meaningful levels of GLP-1, shown by an increase in feelings of fullness and a decrease in hunger, and how long an elevated level of GLP-1 lasts after starch consumption. Researchers aim to address two questions: What amount of SDC maximizes GLP-1-mediated satiety, and does the impact to satiety continue in a second meal? The overall goal is to maximize ileal-digesting SDC's potential use as a food-based agent for weight loss.
Researchers will compare 20, 40, and 60 g of raw corn starch compared to a maltodextrin control on total plasma GLP-1 concentrations, insulin, and blood glucose at baseline, 15, 30, 60, 90, 120, and 180 minutes post-consumption of SDC. Researchers will also measure satiety at baseline, 15, 30, 45, 60, 90, 120, 150, 180 minutes and after a second meal.
Read more
There will be a total of 4 study visits with a least a 7-day break between visits. At each study visit, participants will:
- Consume a randomized test beverage (SDC or maltodextrin)
- Receive a blood draw at 7x over 3 h
- Take a satiety questionnaire 10x over 3 h
- Consume a standardized lunch 3 h after the test beverage consumption
- Conditions
- Blood Glucose, GLP-1, Satiety, Second Meal Intake, Healthy Participant Study
- Being tested
- Maltodextrin (Placebo), Raw Corn Starch
- Keywords
- GLP-1, Slowly-Digestible Starch, Ileal-Digesting Starch, Dietary Starch, Satiety, Starch, raw corn starch, Blood Glucose
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Maltodextrin (Placebo)Dietary supplement
Also called Control
75 g of maltodextrin diluted in 200 mL of water, taken once at a study visit
Raw Corn StarchDietary supplement
Also called Slowly-Digestible Carbohydrate, Ileal-Digesting Starch
Quantity of raw corn starch will vary between low, medium, and high-dose treatment arms (20, 40, 60 g respectively). Each treatment will total 75 g using maltodextrin to account for mass difference (55, 35, 15 g respectively).
| Study group | Role | What they receive |
|---|---|---|
| Maltodextrin | Placebo comparator | Maltodextrin increases GLP-1 from 0-60 minutes but doesn't have an extended or elevated plasma GLP-1 into 2-3 hrs post-consumption. Participants will consume a treatment that is either entirely maltodextrin or partially maltodextrin during each of the 4 study visits. Receives: Dietary Supplement: Maltodextrin (Placebo) |
| Low-Dose SDC | Experimental | 20 g of raw corn starch (SDC) + 55g of maltodextrin = 75 g total Researchers hypothesize that raw corn starch will have an extended or elevated plasma GLP-1 into 2-3 hrs post-consumption. Participants will consume the low-dose once during one of the study visits. Receives: Dietary Supplement: Maltodextrin (Placebo); Dietary Supplement: Raw Corn Starch |
| Medium-Dose SDC | Experimental | 40 g of raw corn starch (SDC) + 35g of maltodextrin = 75 g total Researchers hypothesize that raw corn starch will have an extended or elevated plasma GLP-1 into 2-3 hrs post-consumption. Participants will consume the medium-dose once during one of the study visits. Receives: Dietary Supplement: Maltodextrin (Placebo); Dietary Supplement: Raw Corn Starch |
| High-Dose SDC | Experimental | 60 g of raw corn starch (SDC) + 15g of maltodextrin = 75 g total Researchers hypothesize that raw corn starch will have an extended or elevated plasma GLP-1 into 2-3 hrs post-consumption. Participants will consume the high-dose once during one of the study visits. Receives: Dietary Supplement: Maltodextrin (Placebo); Dietary Supplement: Raw Corn Starch |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total GLP-1 Secretion
To determine the impact of 20, 40, 60 g of SDC compared to a maltodextrin control on total plasma GLP-1 concentrations at baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of SDC. Assessed via spun blood plasma and ELISA Total GLP-1 Kits.
Measured: From baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of treatment for each participant over the course of the 4 arms.
Secondary outcomes (3)
Satiety
Measure satiety at baseline, 15, 30, 45, 60, 90, 120, 150, 180 minutes and after a second meal via satiety questionnaires
Measured: From baseline, 15, 30, 45, 60, 90, 120, 150, 180 minutes and after a second meal for each participant over the course of the 4 arms.
Blood Glucose
To determine the impact of 20, 40, 60 g of SDC compared to a maltodextrin control on total plasma glucose concentrations at baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of SDC. Assessed via spun blood serum.
Measured: From baseline, and 15, 30, 60, 90, 120, and 180 minutes post-consumption for each participant over the course of the 4 arms
Insulin
To determine the impact of 20, 40, 60 g of SDC compared to a maltodextrin control on insulin concentrations at baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of SDC. Assessed via spun blood plasma.
Measured: From baseline, and 15, 30, 60, 90, 120, and 180 minutes post-consumption for each participant over the course of the 4 arms
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 May 2026
- Study start2 Jun 2026
- Primary completion27 Aug 2026
- Study completion27 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Blood GlucoseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- an acute double-blind crossover randomly controlled clinical trial (RCT)
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 17 participants (actual)
Sponsor and investigators
- Lead sponsor
- Purdue University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Bruce R. Hamaker, Purdue University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07572513
- Sponsor's protocol ID
- IRB-2025-00000283
- Status last verified
- Nov 2026
- First submitted
- 1 May 2026
- Last updated
- 6 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Slowly Digestible Carbohydrates for GLP-1 Secretion
- ClinicalTrials.gov ID
- NCT07572513
- Acronym / sponsor ID
- IRB-2025-00000283
- Conditions
- Blood Glucose, GLP-1, Satiety, Second Meal Intake, Healthy Participant Study
- Keywords
- GLP-1, Slowly-Digestible Starch, Ileal-Digesting Starch, Dietary Starch, Satiety, Starch, raw corn starch, Blood Glucose
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 17 participants (actual)
- Lead sponsor
- Purdue UniversityUniversity, hospital or other
- Study start
- 2 Jun 2026 (actual)
- Primary completion
- 27 Aug 2026 (actual)
- Study completion
- 27 Aug 2026 (actual)
- First posted
- 7 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trail is to learn if the hormone, glucagon-like peptide-1 (GLP-1), is stimulated by slowly digestible carbohydrates (SDCs) in healthy adults. In the current study, researchers will observe the amount of SDC that results in clinically meaningful levels of GLP-1, shown by an increase in feelings of fullness and a decrease in hunger, and how long an elevated level of GLP-1 lasts after starch consumption. Researchers aim to address two questions: What amount of SDC maximizes GLP-1-mediated satiety, and does the impact to satiety continue in a second meal? The overall goal is to maximize ileal-digesting SDC's potential use as a food-based agent for weight loss.
Researchers will compare 20, 40, and 60 g of raw corn starch compared to a maltodextrin control on total plasma GLP-1 concentrations, insulin, and blood glucose at baseline, 15, 30, 60, 90, 120, and 180 minutes post-consumption of SDC. Researchers will also measure satiety at baseline, 15, 30, 45, 60, 90, 120, 150, 180 minutes and after a second meal.
There will be a total of 4 study visits with a least a 7-day break between visits. At each study visit, participants will:
- Consume a randomized test beverage (SDC or maltodextrin)
- Receive a blood draw at 7x over 3 h
- Take a satiety questionnaire 10x over 3 h
- Consume a standardized lunch 3 h after the test beverage consumption
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
- Model description
- an acute double-blind crossover randomly controlled clinical trial (RCT)
| Arm | Type | Receives |
|---|---|---|
| Maltodextrin | Placebo comparator | Dietary Supplement: Maltodextrin (Placebo)Maltodextrin increases GLP-1 from 0-60 minutes but doesn't have an extended or elevated plasma GLP-1 into 2-3 hrs post-consumption. Participants will consume a treatment that is either entirely maltodextrin or partially maltodextrin during each of the 4 study visits. |
| Low-Dose SDC | Experimental | Dietary Supplement: Maltodextrin (Placebo), Dietary Supplement: Raw Corn Starch20 g of raw corn starch (SDC) + 55g of maltodextrin = 75 g total Researchers hypothesize that raw corn starch will have an extended or elevated plasma GLP-1 into 2-3 hrs post-consumption. Participants will consume the low-dose once during one of the study visits. |
| Medium-Dose SDC | Experimental | Dietary Supplement: Maltodextrin (Placebo), Dietary Supplement: Raw Corn Starch40 g of raw corn starch (SDC) + 35g of maltodextrin = 75 g total Researchers hypothesize that raw corn starch will have an extended or elevated plasma GLP-1 into 2-3 hrs post-consumption. Participants will consume the medium-dose once during one of the study visits. |
| High-Dose SDC | Experimental | Dietary Supplement: Maltodextrin (Placebo), Dietary Supplement: Raw Corn Starch60 g of raw corn starch (SDC) + 15g of maltodextrin = 75 g total Researchers hypothesize that raw corn starch will have an extended or elevated plasma GLP-1 into 2-3 hrs post-consumption. Participants will consume the high-dose once during one of the study visits. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Healthy population
- BMI between 18.5 and 24.9 kg/m2
- Adults 18 - 45 years old
- Men or women
- Able to read/speak English
Key exclusion criteria (7 listed)
- Participants with 18 > Years of Age > 45 will be excluded.
- Subjects with 18.5 kg/m² > BMI > 24.9 kg/m² will be excluded.
- Diabetic individuals will be excluded.
- Individuals with history of gastrointestinal disease will be excluded from the study.
- Pregnant or nursing women will also be excluded.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Maltodextrin (Placebo)Also: Control75 g of maltodextrin diluted in 200 mL of water, taken once at a study visit | Dietary supplement | High-Dose SDC, Low-Dose SDC, Maltodextrin, Medium-Dose SDC |
| Raw Corn StarchAlso: Slowly-Digestible Carbohydrate, Ileal-Digesting StarchQuantity of raw corn starch will vary between low, medium, and high-dose treatment arms (20, 40, 60 g respectively). Each treatment will total 75 g using maltodextrin to account for mass difference (55, 35, 15 g respectively). | Dietary supplement | High-Dose SDC, Low-Dose SDC, Medium-Dose SDC |
Primary outcome
Total GLP-1 Secretion
Time frame: From baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of treatment for each participant over the course of the 4 arms.
To determine the impact of 20, 40, 60 g of SDC compared to a maltodextrin control on total plasma GLP-1 concentrations at baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of SDC. Assessed via spun blood plasma and ELISA Total GLP-1 Kits.
3 secondary outcomes
Satiety
Time frame: From baseline, 15, 30, 45, 60, 90, 120, 150, 180 minutes and after a second meal for each participant over the course of the 4 arms.
Blood Glucose
Time frame: From baseline, and 15, 30, 60, 90, 120, and 180 minutes post-consumption for each participant over the course of the 4 arms
Insulin
Time frame: From baseline, and 15, 30, 60, 90, 120, and 180 minutes post-consumption for each participant over the course of the 4 arms
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Nov 2026.
- Individual participant dataSharing planned: No
Related trials for Blood Glucose
RecruitingObservational study
Glucose Levels and Outcomes in Women - Mid Pregnancy
Pregnancy
Enrolling by invitationEarly Phase 1
Truway Diagnostic Tools in Primary Care
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Not yet recruiting
A Nurse-Led Digital Coaching Program to Improve Blood Sugar Control in Adults With Type 2 Diabetes
Type 2 Diabetes Mellitus
Not yet recruiting
A Study to Lower Blood Pressure One Year After Childbirth in Women Who Had Preeclampsia
Adverse Pregnancy Outcomes, Cardiovascular Diseases
Not yet recruitingEarly Phase 1
Human Cerebrovascular Blood Flow and Sex Differences in Metabolic Syndrome
Metabolic Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Raw Corn Starch in people with Blood Glucose and GLP-1, run by Purdue University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total GLP-1 Secretion (time frame: From baseline and 15, 30, 60, 90, 120, and 180 minutes post-consumption of treatment for each participant over the course of the 4 arms.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Nov 2026.